

Cryptococcosis Market is estimated to be US\$ 6.74 billion by 2030 with a CAGR of 5.40% during the forecast period

Cryptococcosis Market accounted for US\$ 4.37 billion in 2020 and is estimated to be US\$ 6.74 billion by 2030 and is anticipated to register a CAGR of 5.40%. The fungi *Cryptococcus neoformans* and *Cryptococcus gattii* produce cryptococcosis, which is an infectious disease. Pigeon droppings enhance the soil, hence they're mostly found there. It is disseminated by inhaling fungus, which causes a lung infection, which then spreads to the brain, resulting in meningoencephalitis. Confusion, fever, headache, blurred vision, swollen glands, weight loss, breathing difficulty, chest discomfort, weariness, neck stiffness, nausea, and vomiting are all symptoms of this condition.

The report " Global Cryptococcosis Market, By Treatment (Amphotericin B, Flucytosine, Fluconazole, Voriconazole, Surgery Treatment, Others), By Diagnosis (Bronchoscopy, X-ray, MRI, Lung Biopsy, CSF Polymerase Chain Reaction (PCR), CT Scan, Others), By End-Users (Clinic, Hospital, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030"

Key Highlights:

- On 14th December 2021, The supplemental New Drug Application (sNDA) for XELJANZ® / XELJANZ® XR (tofacitinib) for the treatment of adults with active ankylosing spondylitis (AS) who have had an inadequate response or intolerance to one or more tumour necrosis factor (TNF) blockers has been approved by the US Food and Drug Administration (FDA).

Analyst View:

The growing number of HIV patients around the world is propelling the industry forward. Cryptococcosis has been determined to be the cause of death in 15% of HIV patients, according to reports. HIV patients are immunocompromised and have a weakened immune system, making it easy for the fungus to enter. People in developing nations are not diagnosed early due to a lack of diagnostic tests, which has an impact on the market. Several government agencies are working to eradicate the disease, and advances in detection and treatment are propelling the market.

To know the upcoming trends and insights prevalent in this market, click the link below:

https://www.prophecymarketinsights.com/market_insight/Global-Cryptococcosis-Market-4824

Key Market Insights from the report:

Global Cryptococcosis Market accounted for US\$ 4.37 billion in 2020 and is estimated to be US\$ 6.74 billion by 2030 and is anticipated to register a CAGR of 5.40%. The Global Cryptococcosis Market is segmented based on treatment, diagnosis, end-user, distribution channel and region.

- Based on Treatment, Global Cryptococcosis Market is segmented into Amphotericin B, Flucytosine, Fluconazole, Voriconazole, Surgery Treatment, Others.
- Based on Diagnosis, Global Cryptococcosis Market is segmented into Bronchoscopy, X-ray, MRI, Lung Biopsy, CSF Polymerase Chain Reaction (PCR), CT Scan, Others.
- Based on End-User, Global Cryptococcosis Market is segmented into Clinics, Hospital, Others.
- Based on Distribution Channel, Global Cryptococcosis Market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy.
- By Region, the Global Cryptococcosis Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Competitive Landscape & their strategies of Global Cryptococcosis Market:

The key players operating in the cryptococcosis market are Johnson & Johnson Private Limited, Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., Abbott, Glenmark Pharmaceuticals Limited, Bausch Health Companies Inc., Sigmapharm Laboratories, LLC., Astellas Pharma Inc., MATINAS BIOPHARMA HOLDINGS, INC., NuCare Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co., Ltd., Gilead Sciences, Inc., Jolly Healthcare, Bayer AG, GREENSTONE LLC, Citron Pharma, Hexal AG, Lunan Pharmaceutical Group, B.M. Pharmaceuticals, GlaxoSmithKline plc, Mylan N.V., Takeda Pharmaceutical Company Limited, and Taj Pharmaceuticals Limited, among other domestic and global players.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.